c-Myc and cancer metabolism

Clinical Cancer Research

Volumn 18, Issue 20, 2012, Pages 5546-5553

  Miller, Donald M ^a   Thomas, Shelia D ^a   Islam, Ashraful ^a   Muench, David ^a   Sedoris, Kara ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYC PROTEIN;

BIOGENESIS; CELL PROLIFERATION; DOWN REGULATION; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; GENE TRANSLOCATION; GENETIC TRANSFORMATION; GLYCOLYSIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLIC ACTIVATION; METABOLIC INHIBITION; METABOLIC REGULATION; MITOCHONDRIAL GENE; NONHUMAN; ONCOGENE C MYC; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMINE; GLYCOLYSIS; HUMANS; MITOCHONDRIA; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84867540151     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0977     Document Type: Review

References (100)

1. Morrish F, Neretti N, Sedivy JM, Hockenbery DM. The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 2008;7:1054-66.
2. Wolfer A, Ramaswamy S.MYC and metastasis. Cancer Res 2011;71:2034-7.
3. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 2008;8:976-90.
4. Levens D. You don''t muck with MYC. Genes Cancer 2010;1:547-54.
5. Lombardi L, Newcomb EW, Dalla-Favera R. Pathogenesis of Burkitt lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts. Cell 1987;49:161-70. (Pubitemid 18089603)
6. Teicher BA, Linehan WM, Helman LJ. Targeting cancer metabolism. Clin Cancer Res 2012;18:5537-45.
7. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
8. Warburg O. On respiratory impairment in cancer cells. Science 1956;124:269-70.
9. Koppenol WH, Bounds PL, Dang CV. Otto Warburg''s contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011;11:325-37.
10. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508. (Pubitemid 351355215)
11. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
12. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
13. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76. (Pubitemid 37328911)
14. Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology Am Soc Hematol Educ Program 2007;277-84.
15. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984;4:2486-97. (Pubitemid 15212264)
16. Ciechanover A, DiGiuseppe JA, Schwartz AL, Brodeur GM. Degradation of MYCN oncoprotein by the ubiquitin system. Prog Clin Biol Res 1991;366:37-43.
17. Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc. EMBO J 1999;18:717-26. (Pubitemid 29057256)
18. Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J 2004;23:2116-25. (Pubitemid 38737738)
19. Bahram F, von der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in ineffi cient ubiquitination and decreased proteasome-mediated turnover. Blood 2000;95:2104-10. (Pubitemid 30151652)
20. Sander S, Bullinger L, Wirth T. Repressing the repressor: a new mode of MYC action in lymphomagenesis. Cell Cycle 2009;8:556-9.
21. Sampson VB, Rong NH, Han J, Yang Q, Aris V, Soteropoulos P, et al. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 2007;67:9762-70. (Pubitemid 47621223)
22. Takwi AA, Li Y, Becker Buscaglia LE, Zhang J, Choudhury S, Park AK, et al. A statin-regulated microRNA represses human c-Myc expression and function. EMBO Mol Med 2012;4:896-909.
23. Takaoka Y, Shimizu Y, Hasegawa H, Ouchi Y, Qiao S, Nagahara M, et al. Forced expression of miR-143 represses ERK5/c-Myc and p68/p72 signaling in concert with miR-145 in gut tumors of Apc(Min) mice. PLoS One 2012;7:e42137.
24. Menssen A, Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A 2002;99:6274-9. (Pubitemid 34493302)
25. Coller HA, Grandori C, Tamayo P, Colbert T, Lander ES, Eisenman RN, et al. Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion. Proc Natl Acad Sci U S A 2000;97:3260-5. (Pubitemid 30183289)
26. Lewis BC, Shim H, Li Q,WuCS, Lee LA, Maity A, et al. Identification of putative c-Myc-responsive genes: characterization of rcl, a novel growth-related gene. Mol Cell Biol 1997;17:4967-78. (Pubitemid 27357596)
27. Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol 2003;4:R69.
28. Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, et al. Repression of cyclin D1: a novel function of MYC. Mol Cell Biol 1994;14:4032-43. (Pubitemid 24160809)
29. Guo QM, Malek RL, Kim S, Chiao C, He M, Ruffy M, et al. Identification of c-myc responsive genes using rat cDNA microarray. Cancer Res 2000;60:5922-8.
30. Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010;143:313-24.
31. Duesberg PH, Vogt PK. Avian acute leukemia viruses MC29 and MH2 share specific RNA sequences: evidence for a second class of transforming genes. Proc Natl Acad Sci U S A 1979;76:1633-7. (Pubitemid 9175372)
32. Sheiness D, Bishop JM. DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol 1979;31:514-21. (Pubitemid 9233898)
33. Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 1982;79:7824-7. (Pubitemid 13182471)
34. Shou Y, Martelli ML, Gabrea A, Qi Y, Brents LA, Roschke A, et al. Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. Proc Natl Acad Sci U S A 2000;97:228-33. (Pubitemid 30055813)
35. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010;463:899-905.
36. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A 2006;103:18261-6. (Pubitemid 44871646)
37. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15:6479-83.
38. Eilers M, Eisenman RN. Myc''s broad reach. Genes Dev 2008;22:2755-66.
39. Herkert B, Eilers M. Transcriptional repression: the dark side of myc. Genes Cancer 2010;1:580-6.
40. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A 2006;103:17834-9. (Pubitemid 44852246)
41. Patel JH, Loboda AP, Showe MK, Showe LC, McMahon SB. Analysis of genomic targets reveals complex functions of MYC. Nat Rev Cancer 2004;4:562-8. (Pubitemid 38868625)
42. Armelin HA, Armelin MC, Kelly K, Stewart T, Leder P, Cochran BH, et al. Functional role for c-myc in mitogenic response to platelet-derived growth factor. Nature 1984;310:655-60. (Pubitemid 14054330)
43. Kelly K, Cochran BH, Stiles CD, Leder P. Cell-speci fic regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983;35:603-10. (Pubitemid 14168364)
44. Brooks TA, Hurley LH. Targeting MYC expression through G-Quadruplexes. Genes Cancer 2010;1:641-9.
45. Hurley LH, Von Hoff DD, Siddiqui-Jain A, Yang D. Drug targeting of the c-MYC promoter to repress gene expression via a G-quadruplex silencer element. Semin Oncol 2006;33:498-512. (Pubitemid 44142743)
46. Freie BW, Eisenman RN. Ratcheting Myc. Cancer Cell 2008;14:425-6.
47. Dang CV, O'Donnell KA, Juopperi T. The great MYC escape in tumorigenesis. Cancer Cell 2005;8:177-8. (Pubitemid 41317588)
48. Dang CV. Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 2010;70:859-62.
49. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell 2007;12:108-13. (Pubitemid 47199124)
50. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 1997;94:6658-63. (Pubitemid 27281920)
51. Ramanathan A, Wang C, Schreiber SL. Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements. Proc Natl Acad Sci U S A 2005;102:5992-7. (Pubitemid 40594243)
52. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV. Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 2007;27:7381-93. (Pubitemid 350033646)
53. Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-800. (Pubitemid 30621745)
54. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85.
55. Subramanian A, Miller DM. Structural analysis of alpha-enolase. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. J Biol Chem 2000;275:5958-65. (Pubitemid 30115245)
56. Sedoris KC, Thomas SD, Miller DM. Hypoxia induces differential translation of enolase/MBP-1. BMC Cancer 2010;10:157.
57. Valera A, Pujol A, Gregori X, Riu E, Visa J, Bosch F. Evidence from transgenic mice that myc regulates hepatic glycolysis. FASEB J 1995;9:1067-78.
58. Yang H, Ye D, Guan K-L, Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res 2012;18:5562-71.
59. Kim JW, Dang CV. Cancer''s molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-30. (Pubitemid 44521105)
60. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
61. Flier JS, Mueckler MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987;235:1492-5. (Pubitemid 17038084)
62. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol 2011;7:523.
63. Chesney J, Telang S. Regulation of glycolytic and mitochondrial metabolism by Ras. Curr Pharm Biotechnol. 2012 Jun 1. [Epub ahead of print].
64. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129:1261-74. (Pubitemid 46962095)
65. Kawauchi K, Araki K, Tobiume K, Tanaka N. p53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat Cell Biol 2008;10:611-8. (Pubitemid 351627381)
66. Tamada M, Suematsu M, Saya H. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells. Clin Cancer Res 2012;18:5554-61.
67. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003;17:1115-29. (Pubitemid 36534986)
68. Li F,WangY, Zeller KI, Potter JJ, Wonsey DR, O'Donnell KA, et al. Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 2005;25:6225-34.
69. Morrish F, Noonan J, Perez-Olsen C, Gafken PR, Fitzgibbon M, Kelleher J, et al. Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J Biol Chem 2010;285:36267-74.
70. Morrish F, Hockenbery D. Myc''s mastery of mitochondrial mischief. Cell Cycle 2003;2:11-3.
71. Kaadige MR, Elgort MG, Ayer DE. Coordination of glucose and glutamine utilization by an expanded Myc network. Transcription 2010;1:36-40.
72. Wise DR, DeBerardinis RJ, Mancuso A, Sayed N, Zhang XY, Pfeiffer HK, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A 2008;105:18782-7.
73. Klimberg VS, McClellan JL. Claude H. Organ, Jr. Honorary Lectureship. Glutamine, cancer, and its therapy. Am J Surg 1996;172:418-24.
74. Chen MK, Espat NJ, Bland KI, Copeland EM III, Souba WW. Influence of progressive tumor growth on glutamine metabolism in skeletal muscle and kidney. Ann Surg 1993;217:655- 66; discussion 666-7.
75. Reitzer LJ, Wice BM, Kennell D. Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells. J Biol Chem 1979;254:2669-76. (Pubitemid 9196102)
76. Gallagher FA, Kettunen MI, Day SE, Lerche M, Brindle KM. 13C MR spectroscopy measurements of glutaminase activity in human hepatocellular carcinoma cells using hyperpolarized 13C-labeled glutamine. Magn Reson Med 2008;60:253-7.
77. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008;18:54-61. (Pubitemid 351694453)
78. Curthoys NP, Watford M. Regulation of glutaminase activity and glutamine metabolism. Annu Rev Nutr 1995;15:133-59.
79. Le A, Lane AN, Hamaker M, Bose S, Gouw A, Barbi J, et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 2012;15:110-21.
80. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43. (Pubitemid 40839736)
81. Gao P, Tchernyshyov I, Chang TC, Lee YS, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 2009;458:762-5.
82. Yuneva M, Zamboni N, Oefner P, Sachidanandam R, Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J Cell Biol 2007;178:93-105. (Pubitemid 47026405)
83. Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci U S A 2010;107:2037-42.
84. Schreiber SL, Bernstein BE. Signaling network model of chromatin. Cell 2002;111:771-8. (Pubitemid 36106399)
85. Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell 2005;19:523-34. (Pubitemid 41140009)
86. Rahman S, Sowa ME, Ottinger M, Smith JA, Shi Y, Harper JW, et al. The Brd4 extraterminal domain confers transcription activation independent of pTEFb by recruiting multiple proteins, including NSD3. Mol Cell Biol 2011;31:2641-52.
87. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904-17.
88. Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004;101:1241-6. (Pubitemid 38182673)
89. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697-702. (Pubitemid 40354674)
90. Seo SK, Jin HO, Woo SH, Kim YS, An S, Lee JH, et al. Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol 2011;6:1313-9.
91. Kretzner L, Scuto A, Dino PM, Kowolik CM, Wu J, Ventura P, et al. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res 2011;71:3912-20.
92. Soucek L, Jucker R, Panacchia L, Ricordy R, Tato F, Nasi S. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 2002;62:3507-10. (Pubitemid 34651400)
93. Soucek L, Helmer-Citterich M, Sacco A, Jucker R, Cesareni G, Nasi S. Design and properties of a Myc derivative that efficiently homodimerizes. Oncogene 1998;17:2463-72. (Pubitemid 28544716)
94. Savino M, Annibali D, Carucci N, Favuzzi E, Cole MD, Evan GI, et al. The action mechanism of the Myc inhibitor termed Omomyc may give clues on how to target Myc for cancer therapy. PLoS One 2011;6:e22284.
95. Meijer TWH, Kaanders JHAM, Span PN, Bussink J. Targeting hypoxia, HIF-1 and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res 2012;18:5585-94.
96. Sekhon HS, London CA, Sekhon M, Iversen PL, Devi GR. c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. Lung Cancer 2008;60:347-54.
97. Brown RV, Danford FL, Gokhale V, Hurley LH, Brooks TA. Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directlymediated through the promoter G-quadruplex. J Biol Chem 2011;286:41018-27.
98. Sedoris KC, Thomas SD, Clarkson CR, Muench D, Islam A, Singh R, et al. Genomic c-Myc quadruplex DNA selectively kills leukemia. Mol Cancer Ther 2012;11:66-76.
99. Jerby L, Ruppin E. Predicting drug-targets and biomarkers of cancer via genome-scale metabolic modeling. Clin Cancer Res 2012;18:5572-84.
100. Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 2005;6:635-45. (Pubitemid 41081267)